Loading...
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibito...
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6418474/ https://ncbi.nlm.nih.gov/pubmed/30692121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-11-886457 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|